Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia

M. Oda, K. Isoyama, E. Ito, M. Inoue, M. Tsuchida, H. Kigasawa, Koji Kato, S. Kato

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The Japan Cord Blood Bank Network (JCBBN) reports the treatment of 22 children with acute myeloid leukemia (AML) who received umbilical cord blood transplantation from unrelated donors (CBT) as their second hematopoietic stem cell transplantation (HSCT). Provided by the JCBBN, between February 1997 and September 2006, 22 patients had CBT as a second HSCT. In the initial HSCT, eight received autologous, seven received CBT, and the remaining had allogenic BMT. At the time of CBT as a second HSCT, seven were in the second complete remission (CR2), two in the third CR (CR3), the remaining were not in remission. Reduced intensity conditioning (RIC) conducted for 10 cases and myeloablative conditioning (MAC) for 12 cases. The overall survival rate was 31.3%, 5 years after CBT. Second complete remission at second transplantation was favorable prognosis (58.3 ± 18.6%, compared with 17.1 ± 10.8% for the non-CR group. Mortality after CBT as a second HSCT accounted for 15 cases, 8 from treatment-related mortality. In conclusion, CBT combined with RIC as second HSCT may be useful against a recurrence of AML in children after the initial HSCT.

Original languageEnglish
Pages (from-to)374-382
Number of pages9
JournalInternational journal of hematology
Volume89
Issue number3
DOIs
Publication statusPublished - Apr 1 2009
Externally publishedYes

Fingerprint

Unrelated Donors
Hematopoietic Stem Cell Transplantation
Fetal Blood
Acute Myeloid Leukemia
Transplantation
Pediatrics
Survival
Blood Banks
Japan
Mortality
Survival Rate
Recurrence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. / Oda, M.; Isoyama, K.; Ito, E.; Inoue, M.; Tsuchida, M.; Kigasawa, H.; Kato, Koji; Kato, S.

In: International journal of hematology, Vol. 89, No. 3, 01.04.2009, p. 374-382.

Research output: Contribution to journalArticle

@article{780404c5a603440e941409cb95a5c753,
title = "Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia",
abstract = "The Japan Cord Blood Bank Network (JCBBN) reports the treatment of 22 children with acute myeloid leukemia (AML) who received umbilical cord blood transplantation from unrelated donors (CBT) as their second hematopoietic stem cell transplantation (HSCT). Provided by the JCBBN, between February 1997 and September 2006, 22 patients had CBT as a second HSCT. In the initial HSCT, eight received autologous, seven received CBT, and the remaining had allogenic BMT. At the time of CBT as a second HSCT, seven were in the second complete remission (CR2), two in the third CR (CR3), the remaining were not in remission. Reduced intensity conditioning (RIC) conducted for 10 cases and myeloablative conditioning (MAC) for 12 cases. The overall survival rate was 31.3{\%}, 5 years after CBT. Second complete remission at second transplantation was favorable prognosis (58.3 ± 18.6{\%}, compared with 17.1 ± 10.8{\%} for the non-CR group. Mortality after CBT as a second HSCT accounted for 15 cases, 8 from treatment-related mortality. In conclusion, CBT combined with RIC as second HSCT may be useful against a recurrence of AML in children after the initial HSCT.",
author = "M. Oda and K. Isoyama and E. Ito and M. Inoue and M. Tsuchida and H. Kigasawa and Koji Kato and S. Kato",
year = "2009",
month = "4",
day = "1",
doi = "10.1007/s12185-009-0266-9",
language = "English",
volume = "89",
pages = "374--382",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia

AU - Oda, M.

AU - Isoyama, K.

AU - Ito, E.

AU - Inoue, M.

AU - Tsuchida, M.

AU - Kigasawa, H.

AU - Kato, Koji

AU - Kato, S.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - The Japan Cord Blood Bank Network (JCBBN) reports the treatment of 22 children with acute myeloid leukemia (AML) who received umbilical cord blood transplantation from unrelated donors (CBT) as their second hematopoietic stem cell transplantation (HSCT). Provided by the JCBBN, between February 1997 and September 2006, 22 patients had CBT as a second HSCT. In the initial HSCT, eight received autologous, seven received CBT, and the remaining had allogenic BMT. At the time of CBT as a second HSCT, seven were in the second complete remission (CR2), two in the third CR (CR3), the remaining were not in remission. Reduced intensity conditioning (RIC) conducted for 10 cases and myeloablative conditioning (MAC) for 12 cases. The overall survival rate was 31.3%, 5 years after CBT. Second complete remission at second transplantation was favorable prognosis (58.3 ± 18.6%, compared with 17.1 ± 10.8% for the non-CR group. Mortality after CBT as a second HSCT accounted for 15 cases, 8 from treatment-related mortality. In conclusion, CBT combined with RIC as second HSCT may be useful against a recurrence of AML in children after the initial HSCT.

AB - The Japan Cord Blood Bank Network (JCBBN) reports the treatment of 22 children with acute myeloid leukemia (AML) who received umbilical cord blood transplantation from unrelated donors (CBT) as their second hematopoietic stem cell transplantation (HSCT). Provided by the JCBBN, between February 1997 and September 2006, 22 patients had CBT as a second HSCT. In the initial HSCT, eight received autologous, seven received CBT, and the remaining had allogenic BMT. At the time of CBT as a second HSCT, seven were in the second complete remission (CR2), two in the third CR (CR3), the remaining were not in remission. Reduced intensity conditioning (RIC) conducted for 10 cases and myeloablative conditioning (MAC) for 12 cases. The overall survival rate was 31.3%, 5 years after CBT. Second complete remission at second transplantation was favorable prognosis (58.3 ± 18.6%, compared with 17.1 ± 10.8% for the non-CR group. Mortality after CBT as a second HSCT accounted for 15 cases, 8 from treatment-related mortality. In conclusion, CBT combined with RIC as second HSCT may be useful against a recurrence of AML in children after the initial HSCT.

UR - http://www.scopus.com/inward/record.url?scp=67649234169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649234169&partnerID=8YFLogxK

U2 - 10.1007/s12185-009-0266-9

DO - 10.1007/s12185-009-0266-9

M3 - Article

VL - 89

SP - 374

EP - 382

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -